AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02300779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-residue diet
Description: Subjects will be instructed by members of the research team to follow a low-residue diet for 4 days.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. Their usual treatment for diabetes (whether insulin or an oral agent) will be adjusted.
Study NCT03982693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edetate Disodium
Description: The solution contains up to 3 g of edetate disodium adjusted based on creatinine clearance, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2500 U of heparin, 7 g of ascorbate, 2 milliequivalent (mEq) potassium chloride (KCl), 840 mg sodium bicarbonate, 250 mg pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, and sterile water to complete 500 mL.
Study NCT03982693 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions consist of 500 ml normal saline.
Study NCT02300779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by a liquid-only diet for an additional day.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. No modifications in their usual treatment will be made.
Study NCT00720005 — intervention group
Intervention type: DEVICE
Intervention: Aspheric Acrysof ReSTOR intraocular lens
Description: Bilateral implantation of Aspheric Acrysof ReSTOR
Study NCT01479088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Description: The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value \<180 pg/mL as tolerated by the patient
Study NCT03796169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal notification
Description: Baseline quality indicators of each endoscopist were measured and those were notified individually.
Study NCT03796169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open notification
Description: Quality indicators were measured for 3 months after 1st interventions and those were notified openly
Study NCT03796169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Quality indicators were measured for 3 months after 2nd interventions and educated the importance of colonoscopy quality by a GI faculty
Study NCT04538807 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: electromyography
Description: Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
Study NCT04360330 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Breast Radiotherapy
Description: Preoperative SABER: Participants will be treated with an assigned dose level of preoperative SABER, delivered in once a day, 5 fractions given on non-consecutive days, over a period of 2 weeks. In this phase I study, starting with dose level II, a dose level of preoperative SABER will be assigned per study dose-escalation design, treating 2 to 6 patients per dose level. The tested doses are the following:~* Dose Level I: 35 Gy (5 fractions of 7 Gy)~* Dose Level II (Starting Dose): 40 Gy (5 fractions of 8 Gy)~* Dose Level III: 45 Gy (5 fractions of 9 Gy)~* Dose Level IV: 50 Gy (5 fractions of 10 Gy)
Study NCT01332929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.~For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.~For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week.
Study NCT03835208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High/low carbohydrate distribution
Description: A total of 2x3 days, were the patient follow a detailed diet plan. For 3 days they follow a diet plan where the majority of the carbohydrates are located on either the first part of the day(HMK) or the last part of the day(LMK). 4 days of washout are placed between the two interventions. They will not receive food but will be guided by a trained dietitian and the use of a meal plan.
Study NCT03421847 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rotatory vestibular test
Description: We will measure Depression and Healthy subjects vestibular activity by Rotatory Vestibular tests
Study NCT01096550 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient
Description: Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.
Study NCT01381744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flagellin/F1/V
Description: Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.
Study NCT01096550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Outpatient
Description: Buprenorphine patients receiving 9 or more hours of outpatient counseling.
Study NCT02698592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CelsiusTMDS® 8 mm catheter
Description: After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with CelsiusTMDS® 8 mm catheter, until complete isthmic block is achieved.
Study NCT02698592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermocool® 3.5 mm catheter of irrigated tip
Description: After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® 3.5 mm catheter of irrigated tip, until complete isthmic block is achieved.
Study NCT01381744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS) used as diluent and placebo.
Study NCT02059772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT02059772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micropulse diode laser
Study NCT02698592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocool® SF catheter
Description: After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® SF catheter, until complete isthmic block is achieved.
Study NCT02698761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Care Plan
Description: Care Plan~1. Patient Controlled Analgesia (PCA). PCA will be initiated and managed at the discretion of the Pain Management team.~2. Other Medications. All medications will be given during daytime hours, if possible.~3. Pain Psychology.~4. Physical Therapy. Patient is expected to spend time out of bed by Day 2 participating in light activity.~5. Sleep Hygiene. Patient sleeps between the hours of 10 PM and 5 AM daily. Window blinds open by 8 AM. Patient must be awake and ready to participate in therapy by 9 AM.~6. Extracurricular. TV, phone, computer, and video games only between hours of 4-9 PM (computer okay outside of hours only for school work).~7. Other. Patient will eat meals during regular daytime hours (e.g. breakfast consumed before 9 am) and shower daily.
Study NCT05675280 — intervention group
Intervention type: OTHER
Intervention: Gluten free diet
Description: All subjects initiated a gluten free diet as mandated by their diagnosis of Celiac disease, regardless of the study
Study NCT04724486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate
Description: 0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
Study NCT04724486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
Study NCT04724486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.
Study NCT04724486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.
Study NCT00131560 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: VRX496-Modified Autologous T cells
Description: Genetic: Anti-HIV antisense
Study NCT03053492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duck Duck Punch Play
Description: The behavioral intervention will include playing a hands-free video game custom designed for stroke survivors.
Study NCT03053492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercially Available Game Play
Description: The behavioral intervention will include playing a hands-free video game available off-the-shelf.
Study NCT03572829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. Patients receive concurrent aprepitant 125mg, dexamethasone 12mg, and ondansetron 8mg p.o. on day1. AND then patients received aprepitant 80mg, dexamethasone 8mg on day 2-5 at every chemotherapy cycle.
Study NCT02522338 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: iohexol
Description: 10 ml de l'iohexol (300 mgI/ml)
Study NCT02696278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lesson about vegetables
Description: During the introductory period, children will receive a lesson about vegetables 3 days a week for 3 weeks.
Study NCT02696278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetables
Description: During the introductory period, children will be served vegetables 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive vegetables everyday for 3 weeks during snack time at their daycare center.
Study NCT02696278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hummus
Description: During the introductory period, children will be served hummus, depending on their group assignment, 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive hummus, depending on their group assignment, everyday for 3 weeks during snack time at their daycare center.
Study NCT04724486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
Study NCT04724486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
Study NCT02601001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Description: Omecamtiv mecarbil tablets for oral administration
Study NCT02601001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study NCT02229864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary artery stenting: Absorb BVS
Description: * Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm
Study NCT04018287 — intervention group
Intervention type: OTHER
Intervention: HR-pQCT scans, BMD measurements, bone specific circulating microRNAs (miRNAs)
Description: HR-pQCT scans (XtremeCT, SCANCO Medical, Brütisellen, Switzerland) will be performed in all patients with HPP and all CTRL at the ultradistal radius and the distal tibia, using the manufacturer's standard protocol.~Volumetric bone Mineral density (vBMD) will be carried out. The peripheral trabecular density adjacent to the cortex and the central medullary trabecular density will be automatically evaluated. Bone microstructure including trabecular bone volume fraction, trabecular number, trabecular thickness inhomogeneity of the network, cortical thickness and cortical porosity will be analyzed.~Measurements will be carried out by two well-trained physicians and performed with the latest available software (software version 6.0). Daily crosscalibrations with standardized control phantoms (Moehrendorf, Germany) will be conducted for validation.
Study NCT02231216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhinoseptoplasty
Description: Rhinoseptoplasty without turbinectomy procedure
Study NCT02231216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhinoseptoplasty
Description: Rhinoseptoplasty without turbinectomy procedure
Study NCT02231216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial turbinectomy
Description: After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.
Study NCT02231216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic partial turbinectomy
Description: Endoscopy to medial dislocation of the inferior turbinate with instrument
Study NCT02255591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-adrenaline added gadolinium.
Study NCT02255591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-adrenaline added gadolinium.
Study NCT03488940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 24-hours group
Description: Daily amount of feeding were continuously pumped for 24 hours. Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes(GRV) is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation.
Study NCT03488940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 16-hours group
Description: Daily amount of feeding were continuously pumped for 24 hours.Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation.
Study NCT01080963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: one infusion of 350 mg intraoperatively after disconnection from the heart-lung machine as an add-on to standard antibiotic prophylaxis
Study NCT01080963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: 1500 mg intravenous 30min preoperatively during anesthesia and 1500 mg intravenous intraoperatively after disconnection from the heart-lung machine
Study NCT02342587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
Study NCT02796443 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy (LC)
Description: Removal of the gallbladder via a minimally invasive approach
Study NCT01719120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: CBT for insomnia aims at changing dysfunctional cognitive beliefs and maladaptive behaviors contributed to the maintenance of insomnia. It involves 4 main components including behavioral, cognitive, educational, and relaxation treatments.
Study NCT03722212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: METAglut1
Description: A blood draw is performed on each patient for the METAglut1 test, and sent to Laboratoire CERBA, Saint-Ouen l'Aumône, France, for sample analysis.
Study NCT00683449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Group 1
Description: IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg
Study NCT00683449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MN-221 placebo
Description: i.v. infusion of placebo for 15 minutes
Study NCT00683449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Group 2
Description: i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)
Study NCT00683449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Group 3
Description: i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)
Study NCT02503462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: darunavir 800 mg once daily will be first given together with ritonavir 100 mg once daily for one month (period 1) and then darunavir 800 mg once daily will be given together with cobicistat 150 mg once daily for one month (period 2). Afterwards, all patients will be switched back to darunavir/ritonavir (800/100 mg once daily).
Study NCT02503462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir 100 mg once daily will be used to boost darunavir 800 mg once daily (period 1).
Study NCT02503462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobicistat
Description: cobicistat 150 mg once daily will be used to boost darunavir 800 mg once daily (period 2).
Study NCT03488940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent group
Description: Daily amount of feeding were divided into four meals, each meal are pumped within 60mins through stomach tube.~Enteral nutrition preparations pumping scheme: the initial pumping speed is 200ml/h, and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation.
Study NCT02279329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperpolarized Helium MRI
Description: Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Preliminary studies suggest that 3He MRI may be ideally suited for longitudinal COPD research, which is a likely target application of this novel technology. 3He MRI provides a complementary and alternative method for evaluating COPD and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
Study NCT01361529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLP,dose escalation,MTD
Description: dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
Study NCT01202110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study NCT01835990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko
Description: The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.
Study NCT01835990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IPCs
Description: devices that pneumatically compress the leg, resulting in increased venous blood flow.
Study NCT01469052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
Study NCT01469052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib continuous oral dosing (20 mg twice a day) in the fed state